{"id":"pp1m","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE10 inhibitors block the breakdown of cyclic AMP and cyclic GMP in neurons, leading to enhanced signaling through these second messenger pathways. This mechanism is thought to restore balance in striatal medium spiny neuron activity and may have therapeutic effects in neuropsychiatric and neurodegenerative conditions. The drug is being developed for central nervous system indications where PDE10 inhibition may provide clinical benefit.","oneSentence":"PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:52.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"}]},"trialDetails":[{"nctId":"NCT07268430","phase":"NA","title":"Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-12-18","conditions":"Schizophrenia","enrollment":256},{"nctId":"NCT07075237","phase":"PHASE4","title":"Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-10","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT03345342","phase":"PHASE3","title":"A Study of Paliperidone Palmitate 6-Month Formulation","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Schizophrenia","enrollment":841},{"nctId":"NCT04072575","phase":"PHASE3","title":"A Study of Paliperidone Palmitate 6-Month Formulation","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-19","conditions":"Schizophrenia","enrollment":178},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03713658","phase":"PHASE4","title":"A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-18","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT02713282","phase":"PHASE3","title":"A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2016-04-28","conditions":"Schizophrenia","enrollment":306},{"nctId":"NCT04754750","phase":"PHASE1, PHASE2","title":"Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment","status":"COMPLETED","sponsor":"Calo Psychiatric Center","startDate":"2015-01","conditions":"Schizophrenics","enrollment":72},{"nctId":"NCT01515423","phase":"PHASE3","title":"Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-05","conditions":"Schizophrenia","enrollment":1429}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["R092670"],"phase":"phase_3","status":"active","brandName":"PP1M","genericName":"PP1M","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling. Used for Schizophrenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}